source
- STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggestsThe projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.STAT · 55m ago↗ source
- AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trialAstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…